Competing risks of ventricular tachyarrhythmias and mortality in advanced heart failure: impact of left ventricular ejection fraction

European Heart Journal

5 November 2025
Organised by: Logo
ESC Journals

Abstract

AbstractBackground

Patients with heart failure and low left ventricular ejection fraction (LVEF) are at higher risk of death from ventricular tachycardia or ventricular fibrillation (VT/VF), pump failure, or non-cardiac causes. This study aimed to assess the association between LVEF and VT/VF risk, considering non-arrhythmic mortality as a competing factor.

Methods

The study comprised 5,168 primary prevention implantable cardioverter defibrillator (ICD) recipients from five major trials (MADIT-II, MADIT-CRT, MADIT-RIT, MADIT-RISK, RAID), categorized by LVEF tertiles (EF ≤20%, EF 21-29%, EF 30-35%). Outcomes included VT/VF, VT over 200 BPM or VF, appropriate ICD shocks, and mortality, with Fine and Gray regression models used to adjust for death as a competing risk in arrhythmia outcomes.

Results

At 3 years of follow-up, the cumulative incidence of VT/VF was 28% in patients with LVEF ≤20% (n=1504), 23% in those with LVEF 21–29% (n=2011), and 20% in the LVEF 30-35% (n=1653) group (Gray’s test, p<0.001, Figure). Multivariate analysis revealed that compared to patients with EF >20%, patients with EF ≤20% had significant 23% increased risk of VT/VF (p=0.004), 33% increased risk of fast VT/VF (p=0.001), and 31% increased risk of appropriate ICD shocks (p=0.003), even after accounting for competing risks of death. This increased VT/VF risk in lower EF patients was consistent across different subgroups, including age, sex, presence of CRT-D, and non-ischemic cardiomyopathy. Additionally, patients with EF ≤20% had a 1.5-fold higher risk of all-cause mortality compared to those with EF >20% (p<0.001).

Conclusions

Patients with very low LVEF show a markedly increased risk of VT/VF and ICD shocks, even when considering the competing risk of non-arrhythmic mortality, confirming the potential benefit of ICD therapy in this high-risk population.

Contributors

A Barsheshet
A Barsheshet

Author

Rabin Medical Centre Petah Tikva , Israel

A Erez
A Erez

Author

S Mcnitt
S Mcnitt

Author

M Aktas
M Aktas

Author

W Zareba
W Zareba

Author